Ident. | Authors (with country if any) | Title |
---|
000517 (2013) |
Philip G. Conaghan [Royaume-Uni] ; Patrick Durez [Belgique] ; Rieke E. Alten [Allemagne] ; Gerd-Rüdiger Burmester [Allemagne] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Lars Klareskog [Suède] ; Anca Irinel Catrina [Suède] ; Julie Dicarlo [États-Unis] ; Corine Gaillez [France] ; Manuela Le Bars [France] ; Xianhuang Zhou [États-Unis] ; Charles Peterfy [États-Unis] | Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial |
000518 (2013) |
Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
000519 (2013) |
Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche] | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
000520 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas] | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
000530 (2013) |
J. S. Smolen [Autriche] ; A. Kavanaugh [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; S. Florentinus [France] ; S. S. Rathmann [États-Unis] ; H. Kupper [Allemagne] ; E. C. Keystone [Canada] | THU0209 Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis |
000531 (2013) |
A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France] | THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study |
000533 (2013) |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; F. Guillemin [France] ; B. Fautrel [France] | THU0134 Favorable Outcome, a New Concept for the Evaluation of Health Status in Rheumatoid Arthritis (RA) not so Easy to Achieve: Results from the Espoir Cohort |
000535 (2013) |
S. Godot [France] ; J. E. Gottenberg [France] ; S. Paternotte ; I. Pane [France] ; B. Combe [France] ; J. Sibilia [France] ; R.-M. Flipo ; T. Schaeverbeke ; P. Ravaud [France] ; E. Toussirot ; F. Berenbaum [France] ; X. Mariette [France] ; D. Wendling ; J. Sellam [France] | THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry |
000537 (2013) |
M. Dougados [France] ; K. Kissel [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; T. W. J. Huizinga [Pays-Bas] | THU0093 Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study |
000538 (2013) |
L. Gossec [France] ; S. Rouanet ; G. Steinberg ; B. Combe [France] | THU0063 Does biologic treatment modify the relationship of the variables associated with fatigue in patients with rheumatoid arthritis? The peps study of tocilizumab in real life |
000544 (2013) |
G. R. Burmester [Allemagne] ; A. Rubbert-Roth [Allemagne] ; A. Cantagrel [France] ; S. Hall [Australie] ; P. Leszczynski [Pologne] ; D. Feldman [Brésil] ; M. J. Rangaraj ; G. Roane ; C. Ludivico [États-Unis] ; E. Mysler [Argentine] ; L. Rowell [Royaume-Uni] ; I. Vranic [Royaume-Uni] | SAT0105 Summacta: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy Of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients With Moderate to Severe Ra |
000551 (2013) |
J. Sieper [Allemagne] ; B. Porter-Brown [Royaume-Uni] ; L. Thompson [Royaume-Uni] ; O. Harari [Royaume-Uni] ; M. Dougados [France] | OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial |
000552 (2013) |
F. De Benedetti [Italie] ; N. Ruperto [Italie] ; Z. Zuber [Italie] ; C. Keane [Royaume-Uni] ; O. Harari [Royaume-Uni] ; A. Kenwright [Royaume-Uni] ; R. Cuttica [Italie] ; V. Keltsev [Italie] ; R. Xavier [Italie] ; I. Calvo [Italie] ; I. Nikishina [Italie] ; N. Rubio-Pérez [Italie] ; E. Alekseeva [Italie] ; V. Chasnyk [Italie] ; J. Chavez [Italie] ; G. Horneff [Italie] ; V. Opoka-Winiarska [Italie] ; P. Quartier [France] ; C. Silva [Italie] ; E. Silverman ; A. Spindler ; A. Martini ; D. Lovell ; H. Brunner [États-Unis] | OP0060 Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data from a Phase 3 Trial |
000554 (2013) |
T. W. J. Huizinga [Pays-Bas] ; T. Donka [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; M. Dougados [France] | OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study |
000558 (2013) |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; B. Fautrel [France] | FRI0415 Being younger and living with a partner are important determinants of sustained favorable outcome in early arthritis (EA): Results from the french espoir cohort |
000560 (2013) |
M. Schiff [États-Unis] ; M. Dougados [France] ; R. Fleischmann [États-Unis] ; J. Fay [États-Unis] ; M. Maldonado [États-Unis] | FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons |
000561 (2013) |
J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. Mariette | FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial |
000562 (2013) |
J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France] | FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry |
000563 (2013) |
J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France] | FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra) |
000564 (2013) |
J. S. Smolen [Autriche] ; J. Wollenhaupt [Allemagne] ; P. Durez [Belgique] ; J. Gomez-Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars [France] ; C. Gaillez [France] ; C. Poncet [France] ; R. Westhovens [Belgique] | FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial |
000565 (2013) |
H. Nü Lein ; R. Alten [Allemagne] ; M. Galeazzi [Italie] ; H. M. Lorenz [Allemagne] ; D. Boumpas [Grèce] ; M. T. Nurmohamed [Pays-Bas] ; W. G. Bensen [Canada] ; G. R. Burmester [Allemagne] ; H.-H. Peter [Allemagne] ; F. Rainer [Autriche] ; K. Pavelka [République tchèque] ; M. Chartier ; C. Poncet [France] ; C. Rauch [Allemagne] ; M. Le Bars [France] | FRI0235 Adherence to the recommended dosing regimen of abatacept: results from the international, real-world action study |